{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:04Z","timestamp":1791304324860,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40257-021-00645-0","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:53:24Z","timestamp":1635249204000},"page":"247-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Skin Toxicities with Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"La Placa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"645_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/EDBK_289911","volume":"40","author":"A Deutsch","year":"2020","unstructured":"Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:485\u2013500.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"645_CR2","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","volume":"24","author":"E Raschi","year":"2019","unstructured":"Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F. Serious cutaneous toxicities with immune checkpoint inhibitors in the US food and drug administration adverse event reporting system. Oncologist. 2019;24:e1228\u201331.","journal-title":"Oncologist"},{"key":"645_CR3","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/jdv.16159","volume":"34","author":"DM Barrios","year":"2020","unstructured":"Barrios DM, Phillips GS, Freites-Martinez A, Hsu M, Ciccolini K, Skripnik Lucas A, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020;34:1340\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"645_CR4","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369.","journal-title":"Lancet"},{"key":"645_CR5","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, Masuda N, Sohn JH, Andre VAM, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26:e53\u201365.","journal-title":"Oncologist"},{"key":"645_CR6","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1002\/onco.13684","volume":"26","author":"RS Finn","year":"2021","unstructured":"Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, et al. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 years of follow-up. Oncologist. 2021;26:e749\u201355.","journal-title":"Oncologist"},{"key":"645_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","volume":"44","author":"M Silvestri","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A, Messina C, Bennardo L, Nistic\u00f2 SP, et al. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf. 2021;44:725\u201332.","journal-title":"Drug Saf"},{"key":"645_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","volume":"188","author":"S Chawla","year":"2021","unstructured":"Chawla S, Hill A, Fearfield L, Johnston S, Parton M, Heelan K. Cutaneous toxicities occurring during palbociclib (CDK4\/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience. Breast Cancer Res Treat. 2021;188:535\u201345.","journal-title":"Breast Cancer Res Treat"},{"key":"645_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","volume":"185","author":"P Sollena","year":"2021","unstructured":"Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group, et al. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat. 2021;185:247\u201353.","journal-title":"Breast Cancer Res Treat"},{"key":"645_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4048\/jbc.2021.24.e1","volume":"24","author":"M Mariano","year":"2021","unstructured":"Mariano M, Donati P, Cameli N, Pigliacelli F, Morrone A, Cristaudo A. Ribociclib-induced erythema dyschromicum perstans (ashy dermatosis)-like pigmentation in a metastatic breast cancer patient. J Breast Cancer. 2021;24:117\u201321.","journal-title":"J Breast Cancer"},{"key":"645_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4048\/jbc.2019.22.e44","volume":"22","author":"V L\u00f3pez-G\u00f3mez","year":"2019","unstructured":"L\u00f3pez-G\u00f3mez V, Yarza R, Mu\u00f1oz-Gonz\u00e1lez H, Revilla E, Enrech S, Gonz\u00e1lez-Valle O, et al. Ribociclib-related Stevens\u2013Johnson syndrome: oncologic awareness, case report, and literature review. J Breast Cancer. 2019;22:661\u20136.","journal-title":"J Breast Cancer"},{"issue":"14","key":"645_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jdcr.2021.05.028","volume":"3","author":"DJ Kurtyka","year":"2021","unstructured":"Kurtyka DJ, Mohebbi AD, Burke KT, Cardis MA. Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer. JAAD Case Rep. 2021;3(14):10\u20132.","journal-title":"JAAD Case Rep."},{"key":"645_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjd.19677","volume":"184","author":"E Raschi","year":"2021","unstructured":"Raschi E, La Placa M, Poluzzi E, De Ponti F. The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice. Br J Dermatol. 2021;184:581\u20133.","journal-title":"Br J Dermatol"},{"key":"645_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449\u201366.","journal-title":"Target Oncol"},{"key":"645_CR15","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cancers13081758","volume":"13","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic events with cyclin-dependent kinase 4\/6 inhibitors in the FDA adverse event reporting system. Cancers (Basel). 2021;13:1758.","journal-title":"Cancers (Basel)."},{"key":"645_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186:219\u201327.","journal-title":"Breast Cancer Res Treat"},{"key":"645_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","volume":"157","author":"DD Nguyen","year":"2021","unstructured":"Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021;157:35\u201342.","journal-title":"JAMA Dermatol"},{"key":"645_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00625-4","author":"PM Jedlowski","year":"2021","unstructured":"Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA adverse event reporting system (FAERS) from 2006 to 2020. Am J Clin Dermatol. 2021. https:\/\/doi.org\/10.1007\/s40257-021-00625-4.","journal-title":"Am J Clin Dermatol"},{"issue":"21","key":"645_CR19","doi-asserted-by":"publisher","first-page":"00939","DOI":"10.1016\/j.jaad.2021.04.092","volume":"S0190\u20139622","author":"M Amigo","year":"2021","unstructured":"Amigo M, Hoffman K, Chung C, Lustberg M, Wesolowski R, VanDeusen J, et al. Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase (CDK) 4\/6 inhibitor use. J Am Acad Dermatol. 2021;S0190\u20139622(21):00939\u201347. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.092.","journal-title":"J Am Acad Dermatol"},{"key":"645_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fern\u00e1ndez-Pe\u00f1as P, Santini D, ESMO Guidelines Committee, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines. Ann Oncol. 2021;32:157\u201370.","journal-title":"Ann Oncol"},{"key":"645_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13098","volume":"83","author":"P In\u00e1cio","year":"2017","unstructured":"In\u00e1cio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83:227\u201346.","journal-title":"Br J Clin Pharmacol"},{"key":"645_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","volume":"41","author":"S Watson","year":"2018","unstructured":"Watson S, Chandler RE, Taavola H, H\u00e4rmark L, Grundmark B, Zekarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from Lareb and Uppsala monitoring centre. Drug Saf. 2018;41:203\u201312.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"645_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31\u20139.","journal-title":"Am J Clin Dermatol"},{"key":"645_CR24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/jdv.15508","volume":"33","author":"V Zawar","year":"2019","unstructured":"Zawar V, Bondarde S, Pawar M, Sankalecha S. Nail changes due to chemotherapy: a prospective observational study of 129 patients. J Eur Acad Dermatol Venereol. 2019;33:1398\u2013404.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"645_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-020-00505-3","volume":"21","author":"S Patel","year":"2020","unstructured":"Patel S, John AM, Handler MZ, Schwartz RA. Fixed drug eruptions: an update, emphasizing the potentially lethal generalized bullous fixed drug eruption. Am J Clin Dermatol. 2020;21(3):393\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"10147","key":"645_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(18)31770-7","volume":"392","author":"M La Placa","year":"2018","unstructured":"La Placa M, Chessa MA. Erythema multiforme major with swollen lips and crusted erosions. Lancet. 2018;392(10147):592.","journal-title":"Lancet"},{"key":"645_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","volume":"21","author":"JJ Gao","year":"2020","unstructured":"Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, et al. CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020;21:250\u201360.","journal-title":"Lancet Oncol"},{"issue":"10","key":"645_CR28","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"3","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;3(10):1758835918793326. https:\/\/doi.org\/10.1177\/1758835918793326.","journal-title":"Ther Adv Med Oncol."},{"key":"645_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-019-05261-5","volume":"176","author":"ME Cazzaniga","year":"2019","unstructured":"Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M, NetworkER+. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res Treat. 2019;176:483\u201394.","journal-title":"Breast Cancer Res Treat"},{"key":"645_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jaad.2018.04.046","volume":"79","author":"AK Rzepecki","year":"2018","unstructured":"Rzepecki AK, Cheng H, McLellan BN. Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy. J Am Acad Dermatol. 2018;79:545\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"645_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","volume":"134","author":"C Khouri","year":"2021","unstructured":"Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021;134:14\u201321.","journal-title":"J Clin Epidemiol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00645-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:16:11Z","timestamp":1659104171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00645-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00645-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"6 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emanuel Raschi has received personal fees from Novartis, outside the submitted work. Andrea Ardizzoni has received grants and personal fees from BMS, personal fees from MSD, Eli Lilly, Boehringer, and Pfizer, and grants from Celgene, outside the submitted work. Claudio Zamagni has received grants from Novartis, Roche, Eisai, AstraZeneca, Pfizer, PharmaMar, Tesaro, Pierre Fabre, Ist. Gentili, Teva, Seagen, Eli Lilly, Celgene, MSD, GSK, Amgen, and Daiichi; has received support for attending meetings and\/or travel from Novartis, Roche, Pfizer, PharmaMar, Tesaro, Pierre Fabre, Ist. Gentili, and Celgene; and has participated in data safety monitoring or advisory boards for Novartis, Roche, Eisai, AstraZeneca, Pfizer, PharmaMar, Amgen, Tesaro, Quintiles IMS, Eli Lilly, Celgene, MSD, GSK, and Daiichi. Michele Fusaroli, Michelangelo La Placa, Elisabetta Poluzzi, and Fabrizio De Ponti have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets analysed during the current study are available in the public domain: .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Codes are available upon reasonable request to the authors","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ER conceived the study. ER and MF contributed to design of the study. MF contributed to the acquisition and analysis of data. ER drafted the manuscript. All authors contributed to the interpretation of data, critically revised the manuscript and provided final approval.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. This study is based on anonymous data that can be downloaded from a publicly available source. Therefore, no ethical approval is required.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}